Hims & Hers Health (HIMS) has soared after Hunterbrook Media says that the company could benefit from President-elect Donald ...
Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...
The Food and Drug Administration told a federal judge Thursday that it needs more time to reconsider whether Eli Lilly’s ...
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $25.33 which represents a slight increase of $1.18 or 4.89% from the prior close of $24.15. The stock opened at ...
The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a solid 14% in a week. Much of this move came after the U.S. FDA asked for more time to confirm the shortage of ...
Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...
Hims & Hers' financials are robust, with strong and accelerating revenue growth, growing free cash flow, manageable SBC, and ...
Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term ...
Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
After going short the stock in June based on Hunterbrook Media’s reporting, Hunterbrook Capital said today it is long Hims & Hers Health.